All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

aflibercept 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
vascular endothelial growth factor (VEGF) receptors	4916	862111-32-8

Description:

Molecule	Description
Synonyms: aflibercept eylea AVE0005 ziv-aflibercept zaltrap VEGF Trap	has antiangiogenic activity; consists of the second and third Ig domains of VEGFR1 and VEGFR2, respectively, fusion to the Fc region of IgG1; putative antineoplastic agent that binds all VEGF-A isoforms; possible medicine for eye disorders Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
20	mg	P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
March 25, 2020	PMDA	Bayer Yakuhin, Ltd
Nov. 22, 2012	EMA	Bayer AG
Nov. 18, 2011	FDA	REGENERON PHARMACEUTICALS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Endophthalmitis	1293.34	29.82	251	10227	4434	90613535
Visual acuity reduced	1053.42	29.82	286	10192	23124	90594845
Blindness	851.40	29.82	249	10229	26319	90591650
Eye inflammation	685.24	29.82	163	10315	7688	90610281
Vitritis	605.28	29.82	112	10366	1502	90616467
Visual impairment	540.86	29.82	276	10202	132089	90485880
Blindness unilateral	523.98	29.82	131	10347	7605	90610364
Non-infectious endophthalmitis	522.80	29.82	78	10400	228	90617741
Vitreous floaters	447.81	29.82	115	10363	7434	90610535
Uveitis	426.23	29.82	130	10348	15773	90602196
Blindness transient	394.54	29.82	94	10384	4449	90613520
Eye pain	366.53	29.82	151	10327	44017	90573952
Subretinal fluid	349.67	29.82	62	10416	642	90617327
Retinal haemorrhage	337.87	29.82	87	10391	5677	90612292
Anterior chamber cell	327.20	29.82	59	10419	677	90617292
Vitreous opacities	311.98	29.82	53	10425	417	90617552
Intraocular pressure increased	306.00	29.82	84	10394	7009	90610960
Iridocyclitis	237.84	29.82	60	10418	3601	90614368
Detachment of retinal pigment epithelium	227.86	29.82	41	10437	464	90617505
Retinal oedema	220.31	29.82	45	10433	1031	90616938
Keratic precipitates	211.46	29.82	36	10442	287	90617682
Retinal vasculitis	209.75	29.82	46	10432	1495	90616474
Vision blurred	204.17	29.82	138	10340	110155	90507814
Death	199.80	29.82	254	10224	456297	90161672
Anterior chamber inflammation	188.85	29.82	34	10444	386	90617583
Retinal artery occlusion	181.70	29.82	44	10434	2227	90615742
Vitreous disorder	179.64	29.82	28	10450	118	90617851
Vitreous haemorrhage	175.35	29.82	44	10434	2582	90615387
Vitrectomy	172.43	29.82	29	10449	213	90617756
Intra-ocular injection complication	170.82	29.82	24	10454	38	90617931
Vitreal cells	154.19	29.82	24	10454	100	90617869
Hypopyon	145.28	29.82	31	10447	883	90617086
Macular oedema	143.74	29.82	43	10435	4866	90613103
Anterior chamber flare	139.25	29.82	22	10456	103	90617866
Iritis	133.13	29.82	38	10440	3648	90614321
Retinal occlusive vasculitis	118.88	29.82	21	10457	212	90617757
Bacterial endophthalmitis	107.54	29.82	19	10459	192	90617777
Neovascular age-related macular degeneration	105.89	29.82	21	10457	412	90617557
Eye haemorrhage	105.83	29.82	41	10437	10139	90607830
Proteinuria	95.96	29.82	49	10429	23242	90594727
Choroidal neovascularisation	95.08	29.82	19	10459	388	90617581
Vitreous haze	89.81	29.82	14	10464	59	90617910
Age-related macular degeneration	89.49	29.82	20	10458	709	90617260
Neutropenia	83.86	29.82	116	10362	224788	90393181
Retinal pigment epithelial tear	83.82	29.82	16	10462	255	90617714
Product dose omission issue	82.32	29.82	132	10346	291555	90326414
Hypertensive crisis	80.85	29.82	40	10438	17744	90600225
Inadequate aseptic technique in use of product	78.53	29.82	12	10466	43	90617926
Visual acuity reduced transiently	73.95	29.82	14	10464	213	90617756
Retinal detachment	72.77	29.82	28	10450	6794	90611175
Ocular hyperaemia	71.42	29.82	46	10432	33752	90584217
Macular hole	68.23	29.82	17	10461	968	90617001
Polypoidal choroidal vasculopathy	67.62	29.82	11	10467	64	90617905
Hypertension	67.22	29.82	157	10321	457375	90160594
Corneal oedema	65.97	29.82	19	10459	1882	90616087
Disease progression	64.76	29.82	85	10393	156530	90461439
Retinal vein occlusion	64.61	29.82	20	10458	2536	90615433
Metamorphopsia	61.63	29.82	17	10461	1440	90616529
Hypotony of eye	61.48	29.82	12	10466	216	90617753
Visual field defect	61.03	29.82	25	10453	7141	90610828
Retinal vascular occlusion	59.09	29.82	13	10465	428	90617541
Eye irritation	56.82	29.82	40	10438	33938	90584031
Retinal thickening	53.43	29.82	12	10466	435	90617534
Retinal disorder	52.69	29.82	16	10462	1903	90616066
Ocular hypertension	50.41	29.82	15	10463	1665	90616304
Dry age-related macular degeneration	48.26	29.82	10	10468	246	90617723
Retinal exudates	48.15	29.82	12	10466	684	90617285
Cataract	48.00	29.82	50	10428	72042	90545927
Off label use	43.92	29.82	246	10232	1102006	89515963
Retinal ischaemia	42.42	29.82	10	10468	450	90617519
Retinal vascular disorder	42.21	29.82	9	10469	255	90617714
Chorioretinitis	41.22	29.82	11	10467	822	90617147
Abdominal discomfort	40.81	29.82	4	10474	477324	90140645
Retinal depigmentation	40.80	29.82	9	10469	300	90617669
Product use issue	40.71	29.82	106	10372	329813	90288156
Ocular discomfort	40.28	29.82	18	10460	6352	90611617
Eye oedema	39.93	29.82	13	10465	1939	90616030
Intentional dose omission	39.53	29.82	25	10453	17758	90600211
Retinal tear	39.01	29.82	12	10466	1490	90616479
Corneal deposits	38.95	29.82	9	10469	371	90617598
Amaurosis fugax	38.91	29.82	10	10468	645	90617324
Intraocular lens implant	38.69	29.82	9	10469	382	90617587
Vitreous detachment	37.41	29.82	13	10465	2365	90615604
Arthralgia	37.24	29.82	22	10456	778500	89839469
Glaucoma	36.01	29.82	25	10453	20730	90597239
Macular thickening	35.55	29.82	5	10473	8	90617961
Conjunctival disorder	35.25	29.82	8	10470	304	90617665
Drug intolerance	35.17	29.82	5	10473	447586	90170383
Anterior chamber disorder	34.89	29.82	7	10471	146	90617823
Retinal perivascular sheathing	34.69	29.82	6	10472	53	90617916
Swelling	34.57	29.82	4	10474	419054	90198915
Weight increased	34.45	29.82	4	10474	417923	90200046
Infusion related reaction	34.32	29.82	4	10474	416776	90201193
Syringe issue	34.21	29.82	14	10464	3988	90613981
Subretinal hyperreflective exudation	33.93	29.82	5	10473	13	90617956
Retinal degeneration	33.70	29.82	10	10468	1099	90616870
Eye discharge	32.92	29.82	17	10461	8241	90609728
Vena cava thrombosis	32.77	29.82	12	10466	2540	90615429
Multiple use of single-use product	32.72	29.82	11	10467	1812	90616157
Deposit eye	32.49	29.82	5	10473	19	90617950
Pain	32.10	29.82	41	10437	996300	89621669
Peripheral swelling	31.57	29.82	5	10473	413101	90204868
Stomatitis haemorrhagic	31.23	29.82	6	10472	99	90617870
Multiple-drug resistance	30.98	29.82	16	10462	7760	90610209
Corneal striae	30.90	29.82	5	10473	28	90617941
Ocular vasculitis	30.64	29.82	6	10472	110	90617859
Toxic anterior segment syndrome	30.46	29.82	11	10467	2239	90615730

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Visual acuity reduced	1097.21	27.36	334	11160	17216	42592625
Endophthalmitis	725.19	27.36	180	11314	4253	42605588
Retinal haemorrhage	465.39	27.36	134	11360	5636	42604205
Eye inflammation	448.41	27.36	115	11379	3103	42606738
Non-infectious endophthalmitis	398.11	27.36	68	11426	199	42609642
Blindness	387.88	27.36	155	11339	17823	42592018
Vitritis	380.24	27.36	84	11410	1165	42608676
Subretinal fluid	369.83	27.36	75	11419	668	42609173
Blindness transient	341.72	27.36	90	11404	2699	42607142
Intraocular pressure increased	323.91	27.36	104	11390	6329	42603512
Blindness unilateral	320.79	27.36	99	11395	5289	42604552
Vitreous opacities	315.28	27.36	61	11433	415	42609426
Visual impairment	312.31	27.36	175	11319	42938	42566903
Polypoidal choroidal vasculopathy	255.75	27.36	44	11450	136	42609705
Vitreous floaters	248.73	27.36	77	11417	4153	42605688
Detachment of retinal pigment epithelium	236.12	27.36	50	11444	560	42609281
Eye pain	234.93	27.36	107	11387	16923	42592918
Retinal oedema	234.32	27.36	54	11440	914	42608927
Uveitis	203.60	27.36	81	11413	9177	42600664
Intra-ocular injection complication	185.93	27.36	28	11466	22	42609819
Vitreous haemorrhage	174.19	27.36	53	11441	2694	42607147
Anterior chamber cell	173.37	27.36	37	11457	431	42609410
Anterior chamber inflammation	161.43	27.36	34	11460	370	42609471
Vision blurred	155.13	27.36	123	11371	53576	42556265
Age-related macular degeneration	142.89	27.36	30	11464	321	42609520
Proteinuria	138.81	27.36	83	11411	22900	42586941
Retinal pigment epithelial tear	138.59	27.36	29	11465	305	42609536
Macular hole	137.57	27.36	29	11465	317	42609524
Macular oedema	136.81	27.36	47	11447	3522	42606319
Vitrectomy	135.90	27.36	25	11469	124	42609717
Choroidal neovascularisation	130.63	27.36	27	11467	266	42609575
Vitreous disorder	120.08	27.36	23	11471	147	42609694
Retinal vasculitis	118.79	27.36	29	11465	634	42609207
Eye haemorrhage	105.26	27.36	42	11452	4788	42605053
Hypopyon	104.04	27.36	25	11469	510	42609331
Dry age-related macular degeneration	102.66	27.36	19	11475	98	42609743
Retinal artery occlusion	100.03	27.36	33	11461	2182	42607659
Iritis	98.69	27.36	31	11463	1751	42608090
Hypertension	96.08	27.36	166	11328	167038	42442803
Death	95.93	27.36	311	11183	470874	42138967
Retinal detachment	93.08	27.36	42	11452	6483	42603358
Keratic precipitates	89.04	27.36	19	11475	221	42609620
Corneal oedema	86.02	27.36	27	11467	1521	42608320
Vitreal cells	85.63	27.36	15	11479	53	42609788
Colitis microscopic	81.56	27.36	31	11463	3102	42606739
Disease progression	80.35	27.36	141	11353	143515	42466326
Retinal occlusive vasculitis	77.59	27.36	14	11480	61	42609780
Proteus infection	76.22	27.36	24	11470	1366	42608475
Visual acuity reduced transiently	75.70	27.36	15	11479	117	42609724
Diarrhoea	72.78	27.36	280	11214	460569	42149272
Anterior chamber flare	67.88	27.36	13	11481	83	42609758
Neovascular age-related macular degeneration	66.33	27.36	15	11479	232	42609609
Bacterial endophthalmitis	64.25	27.36	13	11481	114	42609727
Ocular hypertension	63.81	27.36	20	11474	1121	42608720
Neutropenia	62.23	27.36	154	11340	199277	42410564
Retinal vein occlusion	60.35	27.36	22	11472	1959	42607882
Induration	60.18	27.36	19	11475	1091	42608750
Prothrombin level decreased	58.94	27.36	19	11475	1167	42608674
Ocular hyperaemia	55.77	27.36	41	11453	15922	42593919
Retinal degeneration	54.95	27.36	16	11478	697	42609144
Retinal thickening	53.96	27.36	14	11480	394	42609447
Drug interaction	53.86	27.36	5	11489	266994	42342847
Product dose omission issue	53.27	27.36	124	11370	154241	42455600
Clostridial infection	52.29	27.36	24	11470	3850	42605991
Serous retinal detachment	50.52	27.36	16	11478	928	42608913
Necrotising fasciitis	48.63	27.36	24	11470	4522	42605319
Ocular vasculitis	44.88	27.36	8	11486	32	42609809
Retinal ischaemia	42.03	27.36	12	11482	487	42609354
Ocular discomfort	41.45	27.36	19	11475	3038	42606803
Iridocyclitis	40.56	27.36	17	11477	2194	42607647
Macular thickening	40.35	27.36	7	11487	23	42609818
Stomatitis	39.90	27.36	58	11436	50271	42559570
Metamorphopsia	39.28	27.36	12	11482	617	42609224
Macular degeneration	38.29	27.36	17	11477	2524	42607317
Neutrophilia	36.19	27.36	21	11473	5471	42604370
Rectal tenesmus	35.90	27.36	13	11481	1135	42608706
Retinal vascular occlusion	35.90	27.36	9	11485	220	42609621
Retinal scar	35.89	27.36	10	11484	371	42609470
Retinal depigmentation	33.77	27.36	7	11487	70	42609771
Vitreous fibrin	33.75	27.36	5	11489	3	42609838
Ocular ischaemic syndrome	33.47	27.36	6	11488	25	42609816
Cardiomyopathy acute	33.33	27.36	7	11487	75	42609766
Visual field defect	32.85	27.36	19	11475	4919	42604922
Skin toxicity	32.77	27.36	21	11473	6528	42603313
Adenocarcinoma metastatic	32.76	27.36	7	11487	82	42609759
Stoma site haemorrhage	32.50	27.36	12	11482	1107	42608734
Intraocular pressure decreased	32.16	27.36	7	11487	90	42609751
Diaphragmatic operation	32.09	27.36	6	11488	33	42609808
Intestinal perforation	31.53	27.36	25	11469	10849	42598992
Retinal vascular disorder	31.37	27.36	8	11486	210	42609631
Eye oedema	30.77	27.36	11	11483	926	42608915
Multiple use of single-use product	30.35	27.36	9	11485	418	42609423
Injury associated with device	29.92	27.36	12	11482	1385	42608456
Vitreous detachment	29.90	27.36	11	11483	1005	42608836
Vitreous haze	29.22	27.36	6	11488	57	42609784
Blood lactic acid increased	28.87	27.36	21	11473	8018	42601823
Scleritis	28.76	27.36	10	11484	776	42609065
Klebsiella infection	28.54	27.36	24	11470	11308	42598533
Cataract	28.32	27.36	38	11456	30566	42579275
Optical coherence tomography abnormal	27.81	27.36	7	11487	174	42609667
Somnolence	27.49	27.36	3	11491	141102	42468739

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Visual acuity reduced	1683.12	25.26	476	17485	31697	110539641
Endophthalmitis	1318.62	25.26	298	17663	7889	110563449
Eye inflammation	871.76	25.26	218	17743	8953	110562385
Vitritis	752.44	25.26	154	17807	2499	110568839
Retinal haemorrhage	674.32	25.26	179	17782	9322	110562016
Subretinal fluid	625.14	25.26	118	17843	1226	110570112
Vitreous opacities	587.32	25.26	105	17856	784	110570554
Blindness	579.48	25.26	219	17742	36140	110535198
Vitreous floaters	489.54	25.26	138	17823	8996	110562342
Uveitis	481.53	25.26	167	17794	21543	110549795
Non-infectious endophthalmitis	466.23	25.26	79	17882	412	110570926
Eye pain	465.68	25.26	205	17756	49894	110521444
Intraocular pressure increased	448.33	25.26	134	17827	10742	110560596
Blindness unilateral	435.79	25.26	128	17833	9658	110561680
Blindness transient	412.01	25.26	110	17851	5846	110565492
Anterior chamber cell	394.38	25.26	79	17882	1142	110570196
Visual impairment	387.71	25.26	252	17709	134176	110437162
Detachment of retinal pigment epithelium	366.74	25.26	72	17889	933	110570405
Retinal oedema	360.38	25.26	77	17884	1550	110569788
Anterior chamber inflammation	328.82	25.26	63	17898	712	110570626
Polypoidal choroidal vasculopathy	327.99	25.26	53	17908	194	110571144
Intra-ocular injection complication	297.72	25.26	43	17918	53	110571285
Retinal vasculitis	294.21	25.26	68	17893	1981	110569357
Vitreous haemorrhage	285.14	25.26	78	17883	4542	110566796
Vision blurred	261.78	25.26	195	17766	128827	110442511
Vitrectomy	259.22	25.26	44	17917	232	110571106
Vitreal cells	240.86	25.26	39	17922	145	110571193
Proteinuria	233.84	25.26	119	17842	39899	110531439
Death	231.25	25.26	409	17552	698460	109872878
Vitreous disorder	230.88	25.26	42	17919	349	110570989
Retinal artery occlusion	226.71	25.26	64	17897	4185	110567153
Keratic precipitates	222.27	25.26	43	17918	513	110570825
Macular oedema	220.02	25.26	70	17891	6896	110564442
Hypopyon	213.20	25.26	49	17912	1391	110569947
Age-related macular degeneration	198.28	25.26	43	17918	930	110570408
Iridocyclitis	190.20	25.26	59	17902	5349	110565989
Retinal pigment epithelial tear	189.62	25.26	37	17924	463	110570875
Anterior chamber flare	185.88	25.26	32	17929	186	110571152
Macular hole	179.25	25.26	40	17921	991	110570347
Choroidal neovascularisation	173.54	25.26	35	17926	524	110570814
Neutropenia	163.72	25.26	249	17712	374371	110196967
Hypertension	162.48	25.26	294	17667	509790	110061548
Disease progression	160.84	25.26	198	17763	243836	110327502
Iritis	156.26	25.26	49	17912	4603	110566735
Eye haemorrhage	135.11	25.26	56	17905	11718	110559620
Retinal occlusive vasculitis	128.56	25.26	24	17937	233	110571105
Corneal oedema	125.98	25.26	38	17923	3135	110568203
Diarrhoea	122.73	25.26	434	17527	1139071	109432267
Retinal detachment	121.34	25.26	51	17910	11049	110560289
Dry age-related macular degeneration	118.22	25.26	23	17938	283	110571055
Vitreous haze	104.35	25.26	18	17943	106	110571232
Visual acuity reduced transiently	99.12	25.26	20	17941	300	110571038
Retinal vein occlusion	93.33	25.26	32	17929	3975	110567363
Neovascular age-related macular degeneration	92.40	25.26	21	17940	566	110570772
Retinal vascular occlusion	90.99	25.26	21	17940	607	110570731
Ocular hyperaemia	90.03	25.26	64	17897	39222	110532116
Colitis microscopic	87.53	25.26	43	17918	13351	110557987
Multiple use of single-use product	85.18	25.26	23	17938	1273	110570065
Metamorphopsia	79.92	25.26	23	17938	1610	110569728
Bacterial endophthalmitis	74.67	25.26	16	17945	326	110571012
Retinal vascular disorder	71.82	25.26	16	17945	393	110570945
Ocular hypertension	71.12	25.26	23	17938	2385	110568953
Visual field defect	70.83	25.26	34	17927	10038	110561300
Inadequate aseptic technique in use of product	70.42	25.26	13	17948	118	110571220
Proteus infection	67.49	25.26	23	17938	2805	110568533
Retinal ischaemia	66.79	25.26	18	17943	989	110570349
Retinal depigmentation	62.53	25.26	14	17947	352	110570986
Hypertensive crisis	61.20	25.26	42	17919	24330	110547008
Retinal thickening	59.25	25.26	13	17948	297	110571041
Retinal exudates	58.03	25.26	17	17944	1267	110570071
Prothrombin level decreased	56.37	25.26	18	17943	1792	110569546
Weight increased	55.90	25.26	3	17958	419641	110151697
Epistaxis	55.83	25.26	86	17875	130286	110441052
Macular thickening	55.46	25.26	9	17952	34	110571304
Retinal degeneration	53.67	25.26	17	17944	1649	110569689
Drug interaction	52.58	25.26	9	17952	500174	110071164
Off label use	52.13	25.26	418	17543	1499767	109071571
Ocular discomfort	51.63	25.26	26	17935	8507	110562831
Retinal disorder	51.61	25.26	18	17943	2352	110568986
Induration	51.47	25.26	18	17943	2371	110568967
Ocular vasculitis	51.25	25.26	10	17951	125	110571213
Cerebral infarction	51.15	25.26	52	17909	51786	110519552
Arthralgia	50.86	25.26	32	17929	779600	109791738
Clostridial infection	49.62	25.26	23	17938	6279	110565059
Serous retinal detachment	49.50	25.26	16	17945	1656	110569682
Dysphonia	48.92	25.26	61	17900	75868	110495470
Pain	47.68	25.26	51	17910	954904	109616434
Eye irritation	47.33	25.26	41	17920	33411	110537927
Nasopharyngitis	46.40	25.26	5	17956	394356	110176982
Necrotising fasciitis	45.55	25.26	23	17938	7568	110563770
Mucosal inflammation	44.82	25.26	66	17895	96075	110475263
No adverse event	43.90	25.26	57	17904	73782	110497556
Abdominal discomfort	43.86	25.26	6	17955	393852	110177486
Retinal scar	43.55	25.26	11	17950	468	110570870
Proctalgia	43.52	25.26	27	17934	13195	110558143
Swelling	42.46	25.26	4	17957	351037	110220301
Pseudoendophthalmitis	42.46	25.26	8	17953	82	110571256
Nephrotic syndrome	42.40	25.26	27	17934	13804	110557534
Vitreous detachment	42.20	25.26	16	17945	2649	110568689
Infusion related reaction	41.99	25.26	6	17955	381156	110190182
Toxic anterior segment syndrome	41.56	25.26	17	17944	3437	110567901
Drug intolerance	41.23	25.26	8	17953	406504	110164834
Retinal perivascular sheathing	40.50	25.26	8	17953	107	110571231
Subretinal hyperreflective exudation	39.77	25.26	6	17955	12	110571326
Retinal tear	39.18	25.26	14	17947	1963	110569375
Hypotony of eye	38.73	25.26	10	17951	465	110570873
Palmar-plantar erythrodysaesthesia syndrome	38.39	25.26	40	17921	40985	110530353
Optical coherence tomography abnormal	37.77	25.26	8	17953	154	110571184
Cataract	37.68	25.26	55	17906	79430	110491908
Rash	37.54	25.26	47	17914	820917	109750421
Neuropathy peripheral	37.44	25.26	87	17874	179190	110392148
Insomnia	36.77	25.26	7	17954	360583	110210755
Corneal deposits	36.48	25.26	10	17951	586	110570752
Haemorrhagic occlusive retinal vasculitis	35.34	25.26	7	17954	95	110571243
Diaphragmatic operation	35.13	25.26	6	17955	33	110571305
Ocular ischaemic syndrome	34.83	25.26	6	17955	35	110571303
Glaucoma	34.72	25.26	29	17932	22488	110548850
Macular fibrosis	34.55	25.26	10	17951	714	110570624
Intestinal perforation	34.44	25.26	28	17933	20916	110550422
Hiccups	34.26	25.26	23	17938	12846	110558492
Retinal neovascularisation	34.15	25.26	8	17953	247	110571091
Rectal tenesmus	33.73	25.26	13	17948	2249	110569089
Retinal cyst	32.33	25.26	7	17954	150	110571188
Pain in extremity	31.71	25.26	20	17941	487098	110084240
Stomatitis	31.46	25.26	106	17855	270136	110301202
Vena cava thrombosis	31.45	25.26	14	17947	3480	110567858
Klebsiella infection	31.33	25.26	26	17935	19983	110551355
Neutrophilia	31.26	25.26	20	17941	10309	110561029
Skin toxicity	31.23	25.26	21	17940	11762	110559576
Maternal exposure during pregnancy	30.56	25.26	3	17958	254880	110316458
Conjunctival hyperaemia	30.19	25.26	16	17945	5815	110565523
Pruritus	30.16	25.26	30	17931	581530	109989808
Diabetic retinal oedema	29.75	25.26	8	17953	436	110570902
Sinusitis	29.74	25.26	6	17955	296682	110274656
Choroidal detachment	29.59	25.26	9	17952	763	110570575
Stoma site haemorrhage	29.53	25.26	12	17949	2386	110568952
Pulmonary embolism	29.40	25.26	89	17872	214385	110356953
Urticaria	28.90	25.26	8	17953	318849	110252489
Lower respiratory tract infection	28.79	25.26	3	17958	243103	110328235
Posterior capsule opacification	28.66	25.26	7	17954	259	110571079
Hypoaesthesia	28.26	25.26	8	17953	314215	110257123
Chorioretinitis	27.96	25.26	10	17951	1405	110569933
Macular degeneration	27.56	25.26	25	17936	21634	110549704
Gastrointestinal toxicity	27.48	25.26	19	17942	11129	110560209
Suspected product quality issue	27.38	25.26	8	17953	591	110570747
Dyspnoea	27.04	25.26	91	17870	1106781	109464557
Colorectal cancer metastatic	26.83	25.26	10	17951	1579	110569759
Anterior chamber disorder	26.28	25.26	6	17955	165	110571173
Adenocarcinoma metastatic	25.83	25.26	7	17954	393	110570945
Cardiomyopathy acute	25.72	25.26	7	17954	399	110570939
Intraocular pressure decreased	25.62	25.26	6	17955	185	110571153
Scleritis	25.62	25.26	14	17947	5406	110565932
Vitreous adhesions	25.59	25.26	5	17956	63	110571275
Asthenia	25.39	25.26	195	17766	688804	109882534
Musculoskeletal stiffness	25.39	25.26	7	17954	279815	110291523
Choroidal haemorrhage	25.38	25.26	6	17955	193	110571145
Conjunctival disorder	25.29	25.26	7	17954	425	110570913

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01XX44	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents
ATC	S01LA05	SENSORY ORGANS OPHTHALMOLOGICALS OCULAR VASCULAR DISORDER AGENTS Antineovascularisation agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D006131	Growth Inhibitors
MeSH PA	D006133	Growth Substances
MeSH PA	D020533	Angiogenesis Inhibitors
FDA MoA	N0000193542	Vascular Endothelial Growth Factor Inhibitors
FDA EPC	N0000193543	Vascular Endothelial Growth Factor Inhibitor
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:39456	antiglaucoma drug
CHEBI has role	CHEBI:66981	ophthalmology drug

Related Drugs by ATC class:

L01XX Other antineoplastic agents 33 drugs

adagrasibaltretamineamsacrineanagrelidearsenic trioxideasparaginasebelzutifancalaspargase pegolcelecoxibdarinaparsindenileukin diftitoxeflornithine show all 33 →

S01LA Antineovascularisation agents 7 drugs

anecortavebevacizumabbrolucizumabfaricimabpegaptanibranibizumabverteporfin

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Central retinal vein occlusion with macular edema	indication	232039004
Branch retinal vein occlusion with macular edema	indication	232048009
Neovascular glaucoma	indication	232086000	DOID:1687
Macular edema due to diabetes mellitus	indication	312912001	DOID:9191
Metastasis from malignant tumor of colon	indication	314998002
Exudative age-related macular degeneration	indication	414173003	DOID:10873
Retinopathy of prematurity	indication	415297005	DOID:13025
Myopic choroidal neovascularization	indication	733124000
Uveitis	contraindication	128473001	DOID:13141

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Vascular endothelial growth factor A	Secreted	P15692	VEGFA_HUMAN	INHIBITOR	Kd	12.30		DRUG LABEL	DRUG LABEL
Placenta growth factor	Secreted	P49763	PLGF_HUMAN	INHIBITOR	Kd	10.41		DRUG LABEL	DRUG LABEL
Vascular endothelial growth factor B	Secreted	P49765	VEGFB_HUMAN	INHIBITOR	Kd	11.72		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
15C2VL427D	UNII
D09574	KEGG_DRUG
4031234	VUID
N0000184016	NUI
4031234	VANDF
4031980	VANDF
C1134659	UMLSCUI
CHEBI:750062	CHEBI
CHEMBL1742982	ChEMBL_ID
DB08885	DRUGBANK_ID
8739	INN_ID
C533178	MESH_SUPPLEMENTAL_RECORD_UI
6786	IUPHAR_LIGAND_ID
1232150	RXNORM
186189	MMSL
192290	MMSL
28208	MMSL
28701	MMSL
d07888	MMSL
014044	NDDF
015046	NDDF
703840003	SNOMEDCT_US
714627007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ZALTRAP	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5840	SOLUTION, CONCENTRATE	100 mg	INTRAVENOUS	BLA	32 sections
ZALTRAP	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5840	SOLUTION, CONCENTRATE	100 mg	INTRAVENOUS	BLA	32 sections
ZALTRAP	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5841	SOLUTION, CONCENTRATE	200 mg	INTRAVENOUS	BLA	32 sections
ZALTRAP	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5841	SOLUTION, CONCENTRATE	200 mg	INTRAVENOUS	BLA	32 sections
PAVBLU	HUMAN PRESCRIPTION DRUG LABEL	1	55513-056	INJECTION, SOLUTION	2 mg	INTRAVITREAL	BLA	30 sections
PAVBLU	HUMAN PRESCRIPTION DRUG LABEL	1	55513-065	INJECTION, SOLUTION	2 mg	INTRAVITREAL	BLA	30 sections
EYLEA	HUMAN PRESCRIPTION DRUG LABEL	1	61755-005	INJECTION, SOLUTION	40 mg	INTRAVITREAL	BLA	31 sections
EYLEA HD	HUMAN PRESCRIPTION DRUG LABEL	1	61755-050	INJECTION, SOLUTION	8 mg	INTRAVITREAL	BLA	31 sections
EYLEA HD	HUMAN PRESCRIPTION DRUG LABEL	1	61755-051	INJECTION, SOLUTION	8 mg	INTRAVITREAL	BLA	31 sections
EYDENZELTboav	HUMAN PRESCRIPTION DRUG LABEL	1	72606-026	INJECTION	2 mg	INTRAVITREAL	BLA	29 sections
AHZANTIVE	HUMAN PRESCRIPTION DRUG LABEL	1	85006-2908	INJECTION, SOLUTION	40 mg	INTRAVITREAL	BLA	16 sections
AHZANTIVE	HUMAN PRESCRIPTION DRUG LABEL	1	85006-2908	INJECTION, SOLUTION	2 mg	INTRAVITREAL	BLA	16 sections